Compare iShares Core High Dividend ETF (HDV) vs Zoetis Inc (ZTS) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
iShares Core High Dividend ETF vs Zoetis Inc — how do they compare? iShares Core High Dividend ETF trades at $29.04, while Zoetis Inc trades at $73.66 (market cap $31.14B). The key difference: Zoetis Inc pays a 2.81% dividend while iShares Core High Dividend ETF pays none, and iShares Core High Dividend ETF is trading nearer its 52-week high, Zoetis Inc nearer its low. Which is the better fit depends on your goals.
| HDV | ZTS | |
|---|---|---|
52-Week High | $29.14 | $156.76 |
52-Week Low | $23.64 | $71.91 |
Market Cap | — | $31.14B |
Sector | — | Health |
Enterprise Value | — | $38.70B |
Dividend Yield | — | 2.81% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
HDV (iShares Core High Dividend ETF) trades at $29.07, up 0.28% with strong bullish technical signals from moving averages. The ETF focuses on high-quality US large-cap dividend stocks, delivering a 3.1% yield while outperforming the S&P 500 by 9 percentage points year-to-date. Recent institutional buying activity from firms like Bay Colony Advisors and 180 Wealth Advisors indicates growing confidence in the fund's income-generating strategy.
The outlook remains positive given HDV's defensive sector weighting and quality screening methodology. Key risks include interest rate sensitivity and market volatility affecting dividend sustainability. Wall Street sentiment is constructive as the ETF continues to attract retirement-focused investors seeking reliable income streams in the current economic environment.
Zoetis (ZTS) trades at $73.4, down 1.95% on the day, as technical indicators signal a bearish trend amid recent price weakness. Fundamentally, the company reported Q2 2026 EPS of $1.87, beating estimates, but revenue was flat and full-year guidance was cut due to softer pet healthcare demand. Analyst sentiment remains mixed with a consensus price target of $94.90, though recent news highlights competitive pressures and a securities class action lawsuit.
The stock presents a value opportunity given its attractive P/E of 12.29 and strong profitability margins, but near-term headwinds from U.S. companion-animal market challenges and legal overhangs pose risks. Upside depends on execution against revised 2026 targets and stabilization in core markets.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
About iShares Core High Dividend ETF
The fund generally will invest at least 80% of its assets in the component securities of its underlying index and in investments that have economic characteristics that are substantially identical to the component securities of its underlying index. The underlying index is comprised of qualified income paying securities that are screened for superior company quality and financial health as determined by Morningstar, Inc.'s proprietary index methodology. The fund is non-diversified.
Read more on HDV →About Zoetis Inc
Zoetis sells anti-infectives, vaccines, parasiticides, diagnostics, and other health products for animals. The firm earns slightly less than half of total revenue from production animals (cattle, pigs, poultry, and so on), and more than half from companion animal (dogs, horses, cats) products make up the other half. Its U.S. business is heavily skewed toward companion animals, while its international business is slightly skewed toward production animals. The firm has the largest market share in the industry and was previously Pfizer's animal health unit.
Read more on ZTS →
